---
title: 'Industry Daily Summary: What Happened on October 28, 2026'
headline: Emcitate debuts as first US drug for MCT8 deficiency
description: Sensorion named Peter Weber chief medical officer, effective November
2.
url: https://thebench.bio/news/industry/2026-10-28
topic: industry
date: '2026-10-28'
covers:
- '2026-10-28'
date_published: '2026-10-28T12:04:00Z'
date_modified: '2026-10-28T12:04:00Z'
tags:
- Clinical
- Industry
sources: 2
publisher: TheBench.Bio
---
# Industry Daily Summary: What Happened on October 28, 2026
**Emcitate debuts as first US drug for MCT8 deficiency**
Sensorion named Peter Weber chief medical officer, effective November 2.
## Today in brief
Emcitate debuted as the first drug for patients with MCT8 deficiency in the United States. [1]
Peter Weber will become Sensorion’s chief medical officer on November 2. [2]
## Also worth knowing
- Sensorion said Weber has expertise in rare genetic ear disorders and has led gene-therapy development for genetic hearing loss. He oversaw inner-ear programs at Decibel Therapeutics and later consulted for Regeneron. [2]
## Also published
- [The biotech bi-weekly: automated nanoparticle formulation, optimized RNA-seq library prep and alginate hydrogel encapsulation in space](), BioTechniques
- [Behind the scenes of 3 Big Pharma layoffs](), BioSpace
## Sources
1. [US MCT8 deficiency patients get 1st drug as Emcitate debuts](), pharmaphorum, 2026-10-28
2. [Weber is new CMO at Sensorion](), Pharmafile, 2026-10-28
---
TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing.
[1]:
[2]: